



Biomarkers in Neurodegenerative Diseases 2.0

Guest Editor:

Dr. Arnab Ghosh

Center for Gene Regulation in
Health and Diseases, Department
of Biological, Geological and
Environmental Sciences,
Cleveland State University,
Cleveland, OH 44115, USA

Deadline for manuscript
submissions:

closed (15 February 2022)

Message from the Guest Editor

Neurodegenerative diseases have presented themselves as significant challenges to the quality of life for millions of people worldwide, affecting an increasing number of people. Researchers and healthcare professionals are undertaking substantial efforts to counter such diseases. Some of the effective approaches include endeavors in basic research areas to better understand the disease mechanisms, identify novel biomarkers for early intervention, improved diagnosis, and experimental medicine for better disease management. We are pleased to announce the second volume of the Special Issue “Biomarkers in Neurodegenerative Diseases”, which will highlight the recent advances in this field. We want to welcome original research articles, reviews, and commentaries highlighting emerging strategies for countering these challenges stemming from neurodegenerative diseases in the future.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)